Thymosin β4 alleviates MAFLD by inhibiting ferroptosis through GPX4 upregulation.320 Additionally, targeting a novel inducible GPX4 isoform could also mitigate ferroptosis and may be used to treat metabolic-associated fatty liver diseases.321 Some existing drugs are being repurposed to treat MAFLD by promoting or inhibiting ferroptosis. The gene discussed is GPX4; the disease is fatty liver disease.